The in vivo results obtained with mAb82 on tumors expressing TRPV6 in an immunodeficient mouse model enable us to obtain proof-of-principle for a monoclonal anti-cancer treatment targeting TRPV6. This evidence concerns the gene TRPV6 and cancer.